Meet the teams
Unlocking the potential of nucleic acids in molecular diagnostics and therapeutics.
CApt Dynamics introduces a cutting-edge platform that uses AI and high dimensional medical devices to discover new compounds that can target, diagnose and potentially treat various diseases.
Team members: Armin Geraili, Dingran Chang
The Kelley Lab, Leslie Dan Faculty of Pharmacy, University of Toronto
Re-engineered cell therapies for improved transplant success.
Myoxa aims to engineer cell therapies that allow a graft to stay alive in low oxygen settings, which is a major shortcoming in using cell-based grafts for clinical therapy.
Team members: Aanshi Gandhi, Aaron Rosenstein, Mohammad Saleh, Danielle Serra, Maria Nguyen
The Garton Lab, Institute of Biomedical Engineering, University of Toronto
Alleviating pathology, treating neurons.
Neuropeutics’ mission is to ameliorate patients’ lives by prioritizing the advancement of small molecule to the clinic, which prevents toxic clumping of a protein involved in neurodegeneration.
Team members: Marc Shenouda, Namita Multan
The Robertson Lab, Department of Laboratory Medicine & Pathobiology, University of Toronto
A point-of-care rapid test that detects urinary tract infections with significantly greater accuracy.
Specific Dx has developed UroStix, which is a paper-based rapid test that can detect urinary tract infections (UTI) with significantly greater accuracy compared to conventional tools in use today.
Team members: Jessican Jenkins, Siobhan Wilson, Jaspreet Randhawa
The Ferenbok Lab, Department of Laboratory Medicine & Pathobiology, University of Toronto
Screening services for effective formula & treatment discovery.
StemTEST is developing a human stem cell derived skin model combined with AI software to objectively test the efficacy of skin products marketed for reducing hyperpigmentation.
Team members: Henry Quach, Kayshani Kanagarajah, Krista Antonio, Yuetong Song
The Wong Lab, Program of Developmental & Stem Cell Biology, The Hospital for Sick Children
Solutions for the eye.
Synakis has developed Syngel, which could replace the natural vitreous in the eye for patients with ocular disorders such as retinal detachment and dry-age-related macular degeneration (AMD).
Team members: Mickael Dang, Adam Forman, Jonathan Labriola
The Shoichet Lab, Institute of Biomedical Engineering, University of Toronto